Paick Jae-Seung, Ku Ja Hyeon, Shin Jae Wook, Yang Ji Hyun, Kim Soo Woong
Department of Urology, Seoul National University College of Medicine, and Seoul Veterans Hospital, Seoul, Korea.
BJU Int. 2006 May;97(5):1017-23. doi: 10.1111/j.1464-410X.2006.06075.x.
To determine the efficacy of an alpha-adrenoceptor antagonist, terazosin, in reducing nocturia in men with lower urinary tract symptoms (LUTS), and to identify the factors predicting treatment outcome.
In all, 100 patients were treated with 2 mg of terazosin once daily for the first 7 days, and continued to receive 4 mg of terazosin once daily for the following 3 weeks. The men were assessed at baseline and at the end of treatment using uroflowmetry, the International Prostate Symptom Score (IPSS), and the degree of nocturia estimated from a frequency-volume chart (FVC) and objectively.
On the FVC, 27 patients reported that the terazosin treatment reduced their nocturia by more than half, and 14 reported a reduction of 25-49%. On the IPSS, 31 patients reported that the treatment reduced their nocturia by more than half and 27 reported a reduction of 25-49%. On multivariate regression analysis, only the actual number of nightly voids on the FVC was associated with a 2.1-fold chance of an improvement of >25% in objective nocturia (P = 0.016). Using a comparable model, a greater nocturia score on the IPSS was associated with a higher likelihood of improvement in subjective nocturia (odds ratio, 1.653; 95% confidence interval, 1.079-2.533; P = 0.021).
Treatment with terazosin can reduce patients' episodes of nocturia both subjectively and objectively in some men with LUTS. Our results suggest that both subjective and objective numbers of nocturia episodes are associated with improvements in subjective and objective nocturnal frequencies, respectively.
确定α-肾上腺素能受体拮抗剂特拉唑嗪对减轻下尿路症状（LUTS）男性患者夜尿症的疗效，并确定预测治疗结果的因素。
总共100例患者在开始的7天内每日服用2 mg特拉唑嗪，随后3周继续每日服用4 mg特拉唑嗪。在基线期和治疗结束时，使用尿流率测定、国际前列腺症状评分（IPSS）以及通过频率-尿量图表（FVC）主观评估和客观评估夜尿症程度对这些男性患者进行评估。
根据FVC，27例患者报告特拉唑嗪治疗使他们的夜尿症减少了一半以上，14例报告减少了25%-49%。根据IPSS，31例患者报告治疗使他们的夜尿症减少了一半以上，27例报告减少了25%-49%。多因素回归分析显示，仅FVC上每晚实际排尿次数与客观夜尿症改善>25%的可能性增加2.1倍相关（P = 0.016）。使用类似模型，IPSS上更高的夜尿症评分与主观夜尿症改善的可能性更高相关（优势比，1.653；95%置信区间，1.079 - 2.533；P = 0.021）。
特拉唑嗪治疗可在主观和客观上减少部分LUTS男性患者的夜尿发作次数。我们的结果表明，主观和客观夜尿发作次数分别与主观和客观夜间排尿频率的改善相关。
